MK0767 in Type 2 Diabetes (0767-012)

Merck Sharp & Dohme (MSD)

Status and phase

Terminated

Phase 2

Conditions

Type 2 Diabetes Mellitus

Treatments

Drug: MK0767

Study type

Interventional

Funder types

Industry

Identifiers

NCT00543556

0767-012

2007_640

Details and patient eligibility

About

This is a clinical trial in patients with Type 2 Diabetes to test the safety of MK0767. This study will also see how effective MK0767 is in lowering markers of glucose metabolism and improving the lipid profile and non-HDL cholesterol when compared with placebo and pioglitazone.

Enrollment

514 patients

Sex

All

Ages

21 to 75 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Type 2 Diabetes Mellitus patients between the ages of 21 and 75 inclusive
Patient is willing to discontinue current therapy for the duration of the study
Patient is not a heavy drinker

Exclusion criteria

Patient has a history of Type 1 diabetes and/or ketoacidosis
Patient has severe diabetic retinopathy, or nephropathy, or neuropath
Patient has has anti-hyperglycemic therapy including insulin, or rosiglitazone and pioglitazone or 2 or more oral agents in combination within 8 weeks prior to visit 1
Patient has a history of, allergy to, intolerance or hypersensitive to troglitazone, rosiglitazone, or pioglitazone including history of elevated liver function test, jaundice, or hepatotoxicity associated with these treatments